Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndromeReport as inadecuate




Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome - Download this document for free, or read online. Document in PDF available to download.

Cardiovascular Diabetology

, 15:157

First Online: 11 November 2016Received: 04 August 2016Accepted: 28 October 2016

Abstract

BackgroundThe potential benefit of SGLT2 inhibitors in metabolic syndrome is with prediabetic stage unclear. This work was undertaken to investigate the non-glycemic effect of empagliflozin on metabolic syndrome rats with prediabetes.

MethodsSHR-NDmcr-cp+-+ rats SHRcp, a model of metabolic syndrome with prediabetes, were given empagliflozin for 10 weeks to examine the effects on urinary sodium and water balance, visceral and subcutaneous adipocyte, and cardiac injury. Further, the effect of empagliflozin on blood pressure and autonomic nervous system was continuously investigated by using radiotelemetry system.

ResultsEmpagliflozin significantly reduced urinary sodium and water balance of SHRcp only within 1 week of the treatment, but later than 1 week did not alter them throughout the treatment. Empagliflozin significantly reduced body weight of SHRcp, which was mainly attributed to the significant reduction of subcutaneous fat mass. Empagliflozin significantly reduced the size of visceral adipocytes and increased the number of smaller size of adipocytes, which was associated with the attenuation of oxidative stress. Empagliflozin ameliorated cardiac hypertrophy and fibrosis of SHRcp, in association with the attenuation of cardiac oxidative stress and inflammation. However, empagliflozin did not significantly change blood pressure, heart rate, sympathetic activity, or baroreceptor function, as evidenced by radiotelemetry analysis.

ConclusionsOur present work provided the evidence that SGLT2 inhibition reduced visceral adipocytes hypertrophy and ameliorated cardiac injury in prediabetic metabolic syndrome rat, independently of diuretic effect or blood pressure lowering effect. Thus, SGLT2 inhibition seems to be a promising therapeutic strategy for prediabetic metabolic syndrome.

KeywordsCardiac protection Oxidative stress Inflammation Metabolic syndrome Prediabetes Natriuresis Adipose tissue AbbreviationsBPblood pressure

LFlow frequency

HRheart rate

sBRGspontaneous baroreceptor reflex function

SGLT-2sodium glucose-cotransporter 2

PIpulse interval

Electronic supplementary materialThe online version of this article doi:10.1186-s12933-016-0473-7 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Hiroaki Kusaka - Nobutaka Koibuchi - Yu Hasegawa - Hisao Ogawa - Shokei Kim-Mitsuyama

Source: https://link.springer.com/article/10.1186/s12933-016-0473-7







Related documents